• 0Shopping Cart
AmideBio LLC
  • ABOUT
  • TEAM
    • Management and Operations
    • Board of Directors
    • Advisory Board
  • SCIENCE
    • Therapeutic Pipeline
    • Discovery
    • Manufacturing
  • PRODUCTS
    • Amyloid Peptides
    • Amyloid Kits and Buffers
    • Bowman-Birk Inhibitors
    • Brazzeins
    • Proinsulin
    • Toxins and Knottins
    • Custom Product Inquiry
    • Request Quote
  • NEWS
  • SUPPORT
    • CONTACT
    • Frequently Asked Questions
    • Application Notes
    • Inquiry Form
  • My Account
    • Checkout
    • Login
  • Search
  • Menu

AmideBio CTO Dr. Michael Stowell’s structural work on a potential novel target for Alzheimer’s published in Nature S.R.

You are here: Home / Privacy Policy / NEWS / AmideBio CTO Dr. Michael Stowell’s structural work on a potential novel t...

AmideBio CTO Dr. Michael Stowell’s structural work on a potential novel target for Alzheimer’s published in Nature S.R.

COMPANY NEWS

  • AMIDEBIO Awarded SBIR Phase I Grant to Develop Novel Glucose Responsive Insulin Therapeutics2021-03-09 - 20:56
  • AMIDEBIO Granted Rare Pediatric Disease Designation by FDA for Novel Solution Stable Glucagon2020-08-20 - 07:40
  • AMIDEBIO Granted Orphan Drug Designation by FDA for Novel Solution Stable Glucagon2020-04-22 - 17:35
  • AMIDEBIO Awarded $1.56M SBIR Phase II Grant to Further Development of its Novel Glucagons for the Treatment of Hyperinsulinism2019-09-30 - 07:33
  • David Brunel Takes Over Chairmanship at AmideBio2018-11-16 - 08:47
Scroll to top